Long antibody HCDR3s from HIV-naïve donors presented on a PG9 neutralizing antibody background mediate HIV neutralization

Proc Natl Acad Sci U S A. 2016 Apr 19;113(16):4446-51. doi: 10.1073/pnas.1518405113. Epub 2016 Apr 4.

Abstract

Development of broadly neutralizing antibodies (bnAbs) against HIV-1 usually requires prolonged infection and induction of Abs with unusual features, such as long heavy-chain complementarity-determining region 3 (HCDR3) loops. Here we sought to determine whether the repertoires of HIV-1-naïve individuals contain Abs with long HCDR3 loops that could mediate HIV-1 neutralization. We interrogated at massive scale the structural properties of long Ab HCDR3 loops in HIV-1-naïve donors, searching for structured HCDR3s similar to those of the HIV-1 bnAb PG9. We determined the nucleotide sequences encoding 2.3 × 10(7)unique HCDR3 amino acid regions from 70 different HIV-1-naïve donors. Of the 26,917 HCDR3 loops with 30-amino acid length identified, we tested 30 for further study that were predicted to have PG9-like structure when chimerized onto PG9. Three of these 30 PG9 chimeras bound to the HIV-1 gp120 monomer, and two were neutralizing. In addition, we found 14 naturally occurring HCDR3 sequences that acquired the ability to bind to the HIV-1 gp120 monomer when adding 2- to 7-amino acid mutations via computational design. Of those 14 designed Abs, 8 neutralized HIV-1, with IC50values ranging from 0.7 to 98 µg/mL. These data suggest that the repertoire of HIV-1-naïve individuals contains rare B cells that encode HCDR3 loops that bind or neutralize HIV-1 when presented on a PG9 background with relatively few or no additional mutations. Long HCDR3 sequences are present in the HIV-naïve B-cell repertoire, suggesting that this class of bnAbs is a favorable target for rationally designed preventative vaccine efforts.

Keywords: HIV; molecular conformation; neutralizing antibodies; protein design.

MeSH terms

  • Amino Acid Substitution
  • Antibodies, Neutralizing* / genetics
  • Antibodies, Neutralizing* / immunology
  • Blood Donors
  • Complementarity Determining Regions*
  • Female
  • HIV Antibodies* / genetics
  • HIV Antibodies* / immunology
  • HIV Envelope Protein gp120 / genetics
  • HIV Envelope Protein gp120 / immunology*
  • HIV-1 / genetics
  • HIV-1 / immunology*
  • Humans
  • Immunoglobulin Heavy Chains* / genetics
  • Immunoglobulin Heavy Chains* / immunology
  • Male
  • Mutation, Missense

Substances

  • Antibodies, Neutralizing
  • Complementarity Determining Regions
  • HIV Antibodies
  • HIV Envelope Protein gp120
  • Immunoglobulin Heavy Chains
  • gp120 protein, Human immunodeficiency virus 1